AFTX-201 Archives - PharmaDeviceNews

Affinia Therapeutics’ AFTX-201 gene therapy is advancing through the UPBEAT trial after receiving FDA Orphan Drug designation for BAG3-associated dilated cardiomyopathy. Representative image.

Affinia Therapeutics advances AFTX-201 gene therapy for BAG3 dilated cardiomyopathy

by Pallavi Madhiraju
July 23, 2026
0 Comments

Affinia Therapeutics gains FDA orphan status for AFTX-201 as the UPBEAT trial tests gene therapy for BAG3 dilated cardiomyopathy.

Pharma & Biotech

What Affinia Therapeutics’ UPBEAT trial reveals about the next phase of inherited heart failure gene therapy

by Pallavi Madhiraju
April 7, 2026
0 Comments

Affinia Therapeutics has cleared AFTX-201 for a Canadian BAG3 DCM trial. Read why the gene therapy’s design and risks matter now.

FDA Fast Track for AFTX-201 raises new expectations for gene therapy in BAG3 cardiomyopathy

Pharma & Biotech

Affinia Therapeutics’ AFTX-201 Fast Track decision highlights rising interest in cardiac gene therapy

by Pallavi Madhiraju
March 4, 2026
0 Comments

Affinia Therapeutics’ AFTX-201 wins FDA Fast Track for BAG3 cardiomyopathy. Explore what this means for cardiac gene therapy and future heart failure treatments.